Section
A 9-year-old girl with atopic dermatitis and relapsing nephrotic syndrome achieved sustained remission of both conditions after dupilumab therapy, enabling withdrawal of steroids and tacrolimus.
Autoimmune neutropenia (AiN) in adults, though rare, is a chronic condition predominantly affecting women with autoimmune comorbidities. Treatment prioritizes observation, with therapies aimed at boosting neutrophil counts or modulating imm
This study reveals that dual BAFF-APRIL blockade with telitacicept distinctly remodels pathogenic autoantibodies in antiphospholipid syndrome, showing differential effects across immunoglobulin isotypes and identifying marrow plasma-cell cl
This article explores distinct immune cell activations in ACPA-positive individuals progressing to rheumatoid arthritis, emphasizing type I interferon activity prior to ultrasound-detectable synovitis and subsequent inflammatory shifts mark
Interim analysis of a phase 3 trial demonstrates povetacicept’s efficacy in reducing proteinuria and pathological markers in IgA nephropathy, with a favorable safety profile.
This review synthesizes phase 3 RAPIDe-3 trial results demonstrating oral deucrictibant’s rapid efficacy and safety for hereditary angioedema attacks, contextualized with phase 2 studies and prophylactic applications, highlighting its
In a phase 2 trial, oral QY201 significantly improved skin outcomes in moderate-to-severe atopic dermatitis with favorable safety, supporting further phase 3 evaluation.
This study reveals that familial hypercholesterolaemia accelerates thymic ageing, reducing thymic output and altering T-cell diversity; statin therapy partially preserves thymic function, suggesting integrated metabolic-immunologic manageme
Ivarmacitinib, a selective JAK1 inhibitor, demonstrated rapid efficacy and immune remodeling in palmoplantar pustulosis over 12 weeks, with favorable safety and potential biomarkers for response stratification.
The AMETHYST Phase 2 trial demonstrated that litifilimab significantly improves skin symptoms in cutaneous lupus erythematosus with a favorable safety profile, marking a potential new targeted treatment for this challenging condition.
In EGPA patients unresponsive to mepolizumab, switching to benralizumab improves lung function, reduces glucocorticoid use, and shows a favorable safety profile, suggesting its potential as an effective alternative treatment.
This study uncovers how HSP70-driven inflammatory interactions between macrophages and stromal cells disrupt the endometrial environment, contributing to recurrent implantation failure by impairing decidualization and immune homeostasis.
This phase 2b trial demonstrates that oral icotrokinra, targeting the interleukin-23 receptor, significantly improves clinical outcomes in moderate to severe ulcerative colitis compared to placebo.
The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.
A large UK study reveals that over two-thirds of biologic-eligible severe asthma patients improve without biologic therapy, identifying distinct exacerbation trajectories linked to blood eosinophil levels and disease phenotype.
This multicenter retrospective study identifies key baseline predictors influencing short-term remission and relapse in pemphigus patients treated with rituximab plus glucocorticoids, guiding personalized treatment strategies.
The PORTOLA phase 2a trial evaluates zetomipzomib, a selective immunoproteasome inhibitor, demonstrating numerically improved biochemical remission and steroid-sparing effects in autoimmune hepatitis patients with inadequate response to sta
Dupilumab treatment in moderate to severe asthma significantly reduces mucus plug burden, resolves existing plugs, limits new plug formation, and decreases plug radiodensity on CT scans, correlating with improved lung function and ventilati
This study reveals that TL1A-activated CD4+ T cells drive distinct cellular and molecular changes in the rectal mucosa of Crohn’s disease patients with perianal fistulising disease (PFD), highlighting a novel TL1A-LTα1β2/IL-22 axis in
This article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emer
